|Security||MRIN / Marin Software Inc. (56804T106)|
|Industry||Computer Processing and Data Preparation and Processing Services|
|Institutional Shares||124,122 - 2.16%|
|Common Shares Outstanding||5,751,000 shares (as of 2018-03-31)|
|Institutional Value||$ 349,000 USD|
Institutional Stock Ownership and Shareholders()
Marin Software Inc. (NASDAQ:MRIN) has 7 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 124,122 shares.
Largest shareholders include
BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., Dimensional Fund Advisors Lp, BlackRock Investment Management, LLC, MetLife Securities, Inc, Springbok Capital Management, Llc, and Barclays Plc.
Marin Software Inc. (NASDAQ:MRIN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/mrin"><img src="https://images.fintel.io/us-mrin-so.png" alt="MRIN / Marin Software Inc. Institutional Ownership"><a>
|MetLife Securities, Inc||4,500||4,500||0.00||11||11||0.00|
|SPRINGBOK CAPITAL MANAGEMENT, LLC||0||800||0||5|
|BlackRock Investment Management, LLC||5,579||5,579||0.00||14||13||-7.14|
|DIMENSIONAL FUND ADVISORS LP||0||12,677||0||84|
|BlackRock Institutional Trust Company, N.A.||13,569||13,569||0.00||34||32||-5.88|
|BlackRock Fund Advisors||84,565||86,989||2.87||213||204||-4.23|
9h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
9h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Related News Stories
There are some signs there is a potential for slowing this, but too little to get excited about. (108-1)
Greetings, and welcome to the Marin Software First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. (8-0)
They're in the final stages of beta testing their cross-platform marketing software, which they've spent about $100 million developing the past four years and already sell to big name customers. (8-4)
as of ET